Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Mahrukh M. Syeda, Georgina V Long, James H. Garrett, Victoria Atkinson, Mario Santinami, Dirk Schadendorf, A. Hauschild, Michael Millward, Mario Mandalà, Vanna Chiarion‐Sileni, Michael Smylie, G. M. Manikhas, Dummer Reinhard, Jennifer Wiggins, Saim Ali, Sachin Bajirao Adnaik, Monique Tan, Maya Dajee, David Polsky